Literature DB >> 3120475

In vivo evaluation of hydroxypyridone iron chelators in a mouse model.

M Gyparaki1, J B Porter, S Hirani, M Streater, R C Hider, E R Huehns.   

Abstract

The 59Fe excretion caused by a range of bidentate N-substituted [R group = methyl (CP20), ethyl (CP21), propyl (CP22), isopropyl (CP23), butyl (CP24) or hexyl (CP25)] 3-hydroxypyrid-4-one chelators in iron-overloaded mice is presented. All the compounds cause significant iron excretion when given intraperitoneally, but that the most hydrophobic compounds, CP24 and CP25, were toxic except at low doses. The excretion caused by CP21, CP22 and CP23 were significantly greater than that caused by CP20 and slightly larger than that caused by an equivalent dose of desferrioxamine. These compounds (CP20 through CP24) also caused significant excretion of 59Fe when administered orally. Compounds CP21, CP22 and CP24 were significantly more active than compounds CP20 and CP23. It is concluded that the N-ethyl or N-propyl 3-hydroxypyrid-4-ones are the most promising compounds for clinical application. Preliminary experiments using a hexadentate pyrid-2-one, CP130, show that this causes significant 59Fe excretion both when given intraperitoneally or orally.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120475     DOI: 10.1159/000205878

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  6 in total

1.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  The inhibition of tyrosinase by pyridinones.

Authors:  R C Hider; K Lerch
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

3.  Investigation of the anti-inflammatory properties of hydroxypyridinones.

Authors:  S D Hewitt; R C Hider; P Sarpong; C J Morris; D R Blake
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

4.  Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94.

Authors:  P Carthew; A G Smith; R C Hider; B Dorman; R E Edwards; J E Francis
Journal:  Biometals       Date:  1994-10       Impact factor: 2.949

5.  Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes.

Authors:  R D Abeysinghe; B L Ellis; J B Porter
Journal:  Eur J Nucl Med       Date:  1994-10

Review 6.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.